Table 3.
Pazopanib and epithelial ovarian carcinoma: clinical trials actively recruiting patients
| Trial | Phase | Estimated enrollment | Regimen | Setting | Primary objective |
|---|---|---|---|---|---|
| NCT0160800985 | Phase I | 17 | Pazopanib → pazopanib + IV paclitaxel → pazopanib maintenance | Recurrent, platinum-resistant EOC | Change in 18F-fluciclatide-retention parameters |
| NCT0160057361 | Phase I/II | 68 | Pazopanib + topotecan | Recurrent, platinum-resistant EOC | I: MTD II: PFS |
| NCT0123877060 | Phase I/II | 57 | Pazopanib + cyclophosphamide | Recurrent, platinum-resistant EOC, PPC, or FTC | I: MTD II: RR |
| NCT0140227186 | Phase I/II | 96 | Pazopanib + carboplatin + paclitaxel | Recurrent, platinum-resistant EOC, PPC, or FTC | I: MTD II: PFS |
| NCT0164482562 | Phase II | 72 | IV paclitaxel ± pazopanib | Recurrent, platinum-resistant EOC | PFS |
| NCT0139235264 | Phase II | 52 | Pazopanib | Solid tumors, including ovarian cancer | Change in endothelial dependent function |
| NCT0161020656 | Phase II | 142 | Gemcitabine ± pazopanib | Recurrent EOC, FTC, or PPC | PFS |
Abbreviations: MTD, maximum tolerated dose; PFS, progression free survival; RR, response rate; EOC, epithelial ovarian cancer; PPC, primary peritoneal carcinoma; FTC, fallopian tube carcinoma; IV, intravenous.